<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774133</url>
  </required_header>
  <id_info>
    <org_study_id>1163/18</org_study_id>
    <nct_id>NCT04774133</nct_id>
  </id_info>
  <brief_title>The Immunodynamic Effect of Radiotherapy in Prostate Cancer Patients.</brief_title>
  <official_title>Radioinduced Modifications of Lymphocyte Subpopulations Involved in Resistence and Escape Mechanisms to Radiation Therapy of Localized Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Paola Nisticò</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Iole Cordone</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Adriana Faiella</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paola Trono</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Serena Masi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roberta Merola</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anna Antenucci</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Laura Foddai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Consiglia Ferriero</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diana Giannarelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paolo Di Ridolfi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy has an important role in the treatment of prostate cancer both as curative&#xD;
      treatment and postoperative or salvage ones. Several studies demonstrated a significant&#xD;
      reduction of lymphocytes during RT but there are only a few studies monitoring these cells in&#xD;
      the treatment of prostate cancer. This study will enroll 50 patients with hystologically&#xD;
      proven prostate cancer who will undergo to radiotherapy according to Institutional protocols.&#xD;
&#xD;
      This study aims to evaluate the effect of RT on immuno-regulatory B, NK, T, B and T&#xD;
      lymphocyte subpopulations (Breg and Treg) and plasma cells, quantitative / qualitative&#xD;
      changes,their correlations with the clinical course of the disease and acute and late&#xD;
      toxicity. In parallel, using multicolor panels (12 colors) we will evaluate the expression of&#xD;
      inhibitory checkpoints and TGFβ signaling.&#xD;
&#xD;
      The final objective is to identify new therapeutic targets to be combined with RT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Actual">February 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to quantify the variation in lymphocyte subpopulations T, NK, B, Breg and Treg,</measure>
    <time_frame>12 months</time_frame>
    <description>quantitative variation</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Pazients will undergo to blood samples at predefined times</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented prostatic cancer&#xD;
&#xD;
          -  Indication to perform radiotherapy treatment&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematological diseases&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Previous neoplasias&#xD;
&#xD;
          -  Prior chemotherapy or other therapies that may have violated the hematopoietic organs&#xD;
&#xD;
          -  Patient's refusal to undergo periodic blood samples&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Sanguineti</last_name>
    <role>Principal Investigator</role>
    <affiliation>IFO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Sanguineti</last_name>
    <phone>0652666125</phone>
    <email>giuseppe.sanguineti@ifo.gov.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paola Franzoso</last_name>
    <phone>0652666125</phone>
    <email>paola.franzoso@ifo.gov.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCSS Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Sanguineti, Head Physician</last_name>
      <email>giuseppe.sanguineti@ifo.gov.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Giuseppe Sanguineti</investigator_full_name>
    <investigator_title>Radioinduced Modifications of Lymphocyte Subpopulations Involved in Resistence and Escape Mechanisms to Radiation Therapy of Localized Prostate Cancer.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

